Stay updated on Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial

Sign up to get notified when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-17T21:57:05.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T22:06:29.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The deletions remove a 403 Forbidden page and the Home link from the study details view, removing the error content and the associated navigation element.
    Difference
    0.5%
    Check dated 2026-09-26T21:40:27.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error, replacing the study details and navigation with a standard error screen, indicating access to the record is currently blocked.
    Difference
    18%
    Check dated 2026-09-19T20:53:18.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The study record now marks the trial as Completed and lists actual start and completion dates (2016-02-16 start; 2026-09-04 completion), replacing the previous Active, not recruiting status and estimates.
    Difference
    0.6%
    Check dated 2026-09-12T19:10:30.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Updated the page revision from v3.6.5 to v3.6.6, indicating a minor metadata update to the study record. This change appears to be limited to the revision tag and does not modify core study details such as eligibility, endpoints, or contacts.
    Difference
    0.1%
    Check dated 2026-08-29T20:06:55.000Z thumbnail image

Stay in the know with updates to Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.